Close Menu

NEW YORK (GenomeWeb) – Bruker reported after the close of the market Thursday that its first quarter revenues rose 7 percent year over year.

For the three months ended March 31, the firm said total revenues rose to $461.4 million from $431.7 million in the first quarter of 2018, beating analysts' consensus estimate of $450.1 million.

Bruker's organic revenue was up 6 percent year over year, while growth from acquisitions was 6 percent, and the negative effect from changes in foreign currency rates was 5 percent.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

In PLOS thos week: transcriptomic and genomic analysis of prostate cancer by ancestry, genes linked to liver function in Korean cohort, and more.

British Columbia is incorporating genomics into its tracking of the ongoing COVID-19 outbreak, Business in Vancouver reports.

An analysis by the Personal Medicine Coalition finds that about a quarter of new drugs approved in 2019 by the US Food and Drug Administration were personalized medicines.

The governor of New York has proposed a five-year plan to study the genomes of people with or who are at high risk of developing Alzheimer's disease.

Mar
31
Sponsored by
Isoplexis

This webinar will discuss the application of single-cell proteomics and immune-imaging in adoptive cell therapy (ACT) for cancer.